-$0.24 EPS Expected for Galmed Pharmaceuticals Ltd (GLMD) This Quarter

Brokerages forecast that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will report ($0.24) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Galmed Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.14). Galmed Pharmaceuticals posted earnings per share of ($0.17) in the same quarter last year, which would suggest a negative year over year growth rate of 41.2%. The business is expected to report its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.51) to ($0.64). For the next year, analysts expect that the company will report earnings of ($1.45) per share, with EPS estimates ranging from ($2.06) to ($0.73). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.02. Galmed Pharmaceuticals had a negative return on equity of 12.23% and a negative net margin of 423.62%.

Several research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Maxim Group reiterated a “buy” rating and set a $20.00 target price on shares of Galmed Pharmaceuticals in a research report on Tuesday, May 7th. Cantor Fitzgerald reiterated a “buy” rating and set a $59.00 target price on shares of Galmed Pharmaceuticals in a research report on Tuesday, February 19th. ValuEngine upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Galmed Pharmaceuticals in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $32.78.

Several institutional investors have recently added to or reduced their stakes in GLMD. BlackRock Inc. purchased a new position in Galmed Pharmaceuticals in the 4th quarter worth approximately $33,000. Northern Trust Corp grew its holdings in shares of Galmed Pharmaceuticals by 16.3% in the fourth quarter. Northern Trust Corp now owns 12,215 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,715 shares during the last quarter. Delek Group Ltd. bought a new position in shares of Galmed Pharmaceuticals in the first quarter worth approximately $173,000. Deutsche Bank AG bought a new position in shares of Galmed Pharmaceuticals in the fourth quarter worth approximately $229,000. Finally, ETF Managers Group LLC grew its holdings in shares of Galmed Pharmaceuticals by 48.9% in the fourth quarter. ETF Managers Group LLC now owns 34,656 shares of the biopharmaceutical company’s stock worth $237,000 after purchasing an additional 11,382 shares during the last quarter. Institutional investors own 35.59% of the company’s stock.

Shares of GLMD traded down $0.19 on Thursday, reaching $6.02. The stock had a trading volume of 65,400 shares, compared to its average volume of 102,703. The stock has a market cap of $133.32 million, a P/E ratio of -11.15 and a beta of 2.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 36.11 and a quick ratio of 36.11. Galmed Pharmaceuticals has a twelve month low of $5.58 and a twelve month high of $27.06.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Further Reading: What are the reasons investors use put options?

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.